Segment disclosures

Company overview

BIO-TECHNE Corp

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

29 dimension combinations 326 retained observations 67 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Changzhou Eminence Biotechnology · Protein Sciences

Consolidated Entities · Statement Business Segments

Source dimensions srt:ConsolidatedEntitiesAxis=tech:ChangzhouEminenceBiotechnologyMember;us-gaap:StatementBusinessSegmentsAxis=tech:ProteinSciencesMember
PeriodValueUnitFiledEvidence
2022-07-01 – 2022-09-302000000 USD20250822Open filing evidence
2021-07-01 – 2022-06-304600000 USD20240822Open filing evidence

Intersegment Elimination · All Other Segments

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:IntersegmentEliminationMember;us-gaap:StatementBusinessSegmentsAxis=us-gaap:AllOtherSegmentsMember
PeriodValueUnitFiledEvidence
2023-07-01 – 2024-06-304153000 USD20250822Open filing evidence

Operating Segments · Consumables · Diagnostics And Genomics

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=tech:ConsumablesMember;us-gaap:StatementBusinessSegmentsAxis=tech:DiagnosticsAndGenomicsMember
PeriodValueUnitFiledEvidence
2023-07-01 – 2024-06-30266348000 USD20240822Open filing evidence
2022-07-01 – 2023-06-30252432000 USD20240822Open filing evidence
2021-07-01 – 2022-06-30243922000 USD20240822Open filing evidence
2020-07-01 – 2021-06-30194948000 USD20230823Open filing evidence
2019-07-01 – 2020-06-30171590000 USD20220824Open filing evidence

Operating Segments · Consumables · Diagnostics And Spatial Biology

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=tech:ConsumablesMember;us-gaap:StatementBusinessSegmentsAxis=tech:DiagnosticsAndSpatialBiologyMember
PeriodValueUnitFiledEvidence
2025-07-01 – 2026-06-30304267000 USD20260824Open filing evidence
2024-07-01 – 2025-06-30283969000 USD20260824Open filing evidence
2023-07-01 – 2024-06-30266348000 USD20260824Open filing evidence
2022-07-01 – 2023-06-30252432000 USD20250822Open filing evidence

Operating Segments · Consumables · Other Revenues From Business Held For Sale

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=tech:ConsumablesMember;us-gaap:StatementBusinessSegmentsAxis=tech:OtherRevenuesFromBusinessHeldForSaleMember
PeriodValueUnitFiledEvidence
2023-07-01 – 2024-06-304153000 USD20240822Open filing evidence

Operating Segments · Consumables · Protein Sciences

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=tech:ConsumablesMember;us-gaap:StatementBusinessSegmentsAxis=tech:ProteinSciencesMember
PeriodValueUnitFiledEvidence
2025-07-01 – 2026-06-30680848000 USD20260824Open filing evidence
2024-07-01 – 2025-06-30684165000 USD20260824Open filing evidence
2023-07-01 – 2024-06-30657679000 USD20260824Open filing evidence
2022-07-01 – 2023-06-30665301000 USD20250822Open filing evidence
2021-07-01 – 2022-06-30646952000 USD20240822Open filing evidence
2020-07-01 – 2021-06-30557037000 USD20230823Open filing evidence
2019-07-01 – 2020-06-30431052000 USD20220824Open filing evidence

Operating Segments · Consumables · All Other Segments

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=tech:ConsumablesMember;us-gaap:StatementBusinessSegmentsAxis=us-gaap:AllOtherSegmentsMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2025-06-304152000 USD20260824Open filing evidence
2023-07-01 – 2024-06-304153000 USD20260824Open filing evidence

Operating Segments · Diagnostics And Genomics

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=tech:DiagnosticsAndGenomicsMember
PeriodValueUnitFiledEvidence
2023-07-01 – 2024-06-30326392000 USD20240822Open filing evidence
2024-01-01 – 2024-03-3187511000 USD20240506Open filing evidence
2023-07-01 – 2024-03-31235715000 USD20240506Open filing evidence
2023-10-01 – 2023-12-3175408000 USD20240207Open filing evidence
2023-07-01 – 2023-12-31148204000 USD20240207Open filing evidence
2023-07-01 – 2023-09-3072797000 USD20231107Open filing evidence
2022-07-01 – 2023-06-30292602000 USD20240822Open filing evidence
2023-01-01 – 2023-03-3175669000 USD20240506Open filing evidence
2022-07-01 – 2023-03-31213577000 USD20240506Open filing evidence
2022-10-01 – 2022-12-3168003000 USD20240207Open filing evidence
2022-07-01 – 2022-12-31137907000 USD20240207Open filing evidence
2022-07-01 – 2022-09-3069904000 USD20231107Open filing evidence
2021-07-01 – 2022-06-30274843000 USD20240822Open filing evidence
2022-01-01 – 2022-03-3177679000 USD20230508Open filing evidence
2021-07-01 – 2022-03-31203191000 USD20230508Open filing evidence
2021-10-01 – 2021-12-3164527000 USD20230207Open filing evidence
2021-07-01 – 2021-12-31125512000 USD20230207Open filing evidence
2021-07-01 – 2021-09-3060985000 USD20221107Open filing evidence
2020-07-01 – 2021-06-30227744000 USD20230823Open filing evidence
2021-01-01 – 2021-03-3158093000 USD20220509Open filing evidence
2020-07-01 – 2021-03-31160687000 USD20220509Open filing evidence
2020-10-01 – 2020-12-3152469000 USD20220207Open filing evidence
2020-07-01 – 2020-12-31102595000 USD20220207Open filing evidence
2020-07-01 – 2020-09-3050125000 USD20211108Open filing evidence
2019-07-01 – 2020-06-30184549000 USD20220824Open filing evidence
2020-01-01 – 2020-03-3149411000 USD20210507Open filing evidence
2019-07-01 – 2020-03-31135808000 USD20210507Open filing evidence
2019-10-01 – 2019-12-3143846000 USD20210208Open filing evidence
2019-07-01 – 2019-12-3186397000 USD20210208Open filing evidence
2019-07-01 – 2019-09-3042552000 USD20201109Open filing evidence
2018-07-01 – 2019-06-30171674000 USD20210825Open filing evidence
2019-01-01 – 2019-03-3147134000 USD20200511Open filing evidence
2018-07-01 – 2019-03-31123144000 USD20200511Open filing evidence
2018-10-01 – 2018-12-3139263000 USD20200206Open filing evidence
2018-07-01 – 2018-12-3176010000 USD20200206Open filing evidence
2018-07-01 – 2018-09-3036747000 USD2019-11-06 · 21:41:35.000ZOpen filing evidence
2017-07-01 – 2018-06-30161151000 USD20200826Open filing evidence
2018-01-01 – 2018-03-3140929000 USD20190507Open filing evidence
2017-07-01 – 2018-03-31114604000 USD20190507Open filing evidence
2017-10-01 – 2017-12-3137086000 USD20190207Open filing evidence
2017-07-01 – 2017-12-3173675000 USD20190207Open filing evidence
2017-07-01 – 2017-09-3036589000 USD20181107Open filing evidence
2016-07-01 – 2017-06-30143742000 USD20191106Open filing evidence

Operating Segments · Diagnostics And Spatial Biology

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=tech:DiagnosticsAndSpatialBiologyMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3080164000 USD2026-11-12 · 21:31:23.000ZOpen filing evidence
2025-07-01 – 2026-06-30336365000 USD20260824Open filing evidence
2026-01-01 – 2026-03-3185586000 USD20260506Open filing evidence
2025-07-01 – 2026-03-31246224000 USD20260506Open filing evidence
2025-10-01 – 2025-12-3181180000 USD20260204Open filing evidence
2025-07-01 – 2025-12-31160638000 USD20260204Open filing evidence
2025-07-01 – 2025-09-3079458000 USD2026-11-12 · 21:31:23.000ZOpen filing evidence
2024-07-01 – 2025-06-30346263000 USD20260824Open filing evidence
2025-01-01 – 2025-03-3189231000 USD20260506Open filing evidence
2024-07-01 – 2025-03-31256558000 USD20260506Open filing evidence
2024-10-01 – 2024-12-3184135000 USD20260204Open filing evidence
2024-07-01 – 2024-12-31167327000 USD20260204Open filing evidence
2024-07-01 – 2024-09-3083192000 USD20251105Open filing evidence
2023-07-01 – 2024-06-30326392000 USD20260824Open filing evidence
2024-01-01 – 2024-03-3187511000 USD20250508Open filing evidence
2023-07-01 – 2024-03-31235715000 USD20250508Open filing evidence
2023-10-01 – 2023-12-3175408000 USD20250206Open filing evidence
2023-07-01 – 2023-12-31148204000 USD20250206Open filing evidence
2023-07-01 – 2023-09-3072797000 USD20241105Open filing evidence
2022-07-01 – 2023-06-30292602000 USD20250822Open filing evidence

Operating Segments · Protein Sciences

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=tech:ProteinSciencesMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30219691000 USD2026-11-12 · 21:31:23.000ZOpen filing evidence
2025-07-01 – 2026-06-30874620000 USD20260824Open filing evidence
2026-01-01 – 2026-03-31226154000 USD20260506Open filing evidence
2025-07-01 – 2026-03-31643426000 USD20260506Open filing evidence
2025-10-01 – 2025-12-31215084000 USD20260204Open filing evidence
2025-07-01 – 2025-12-31417272000 USD20260204Open filing evidence
2025-07-01 – 2025-09-30202188000 USD2026-11-12 · 21:31:23.000ZOpen filing evidence
2024-07-01 – 2025-06-30870245000 USD20260824Open filing evidence
2025-01-01 – 2025-03-31227687000 USD20260506Open filing evidence
2024-07-01 – 2025-03-31643774000 USD20260506Open filing evidence
2024-10-01 – 2024-12-31211551000 USD20260204Open filing evidence
2024-07-01 – 2024-12-31416086000 USD20260204Open filing evidence
2024-07-01 – 2024-09-30204535000 USD20251105Open filing evidence
2023-07-01 – 2024-06-30830902000 USD20260824Open filing evidence
2024-01-01 – 2024-03-31214589000 USD20250508Open filing evidence
2023-07-01 – 2024-03-31616914000 USD20250508Open filing evidence
2023-10-01 – 2023-12-31197670000 USD20250206Open filing evidence
2023-07-01 – 2023-12-31402325000 USD20250206Open filing evidence
2023-07-01 – 2023-09-30204655000 USD20241105Open filing evidence
2022-07-01 – 2023-06-30845747000 USD20250822Open filing evidence
2023-01-01 – 2023-03-31218903000 USD20240506Open filing evidence
2022-07-01 – 2023-03-31622739000 USD20240506Open filing evidence
2022-10-01 – 2022-12-31203887000 USD20240207Open filing evidence
2022-07-01 – 2022-12-31403836000 USD20240207Open filing evidence
2022-07-01 – 2022-09-30199949000 USD20231107Open filing evidence
2021-07-01 – 2022-06-30832311000 USD20240822Open filing evidence
2022-01-01 – 2022-03-31213176000 USD20230508Open filing evidence
2021-07-01 – 2022-03-31615332000 USD20230508Open filing evidence
2021-10-01 – 2021-12-31204971000 USD20230207Open filing evidence
2021-07-01 – 2021-12-31402156000 USD20230207Open filing evidence
2021-07-01 – 2021-09-30197186000 USD20221107Open filing evidence
2020-07-01 – 2021-06-30704564000 USD20230823Open filing evidence
2021-01-01 – 2021-03-31185623000 USD20220509Open filing evidence
2020-07-01 – 2021-03-31512248000 USD20220509Open filing evidence
2020-10-01 – 2020-12-31172179000 USD20220207Open filing evidence
2020-07-01 – 2020-12-31326625000 USD20220207Open filing evidence
2020-07-01 – 2020-09-30154446000 USD20211108Open filing evidence
2019-07-01 – 2020-06-30555352000 USD20220824Open filing evidence
2020-01-01 – 2020-03-31145509000 USD20210507Open filing evidence
2019-07-01 – 2020-03-31428021000 USD20210507Open filing evidence
2019-10-01 – 2019-12-31141517000 USD20210208Open filing evidence
2019-07-01 – 2019-12-31282512000 USD20210208Open filing evidence
2019-07-01 – 2019-09-30140995000 USD20201109Open filing evidence
2018-07-01 – 2019-06-30543159000 USD20210825Open filing evidence
2019-01-01 – 2019-03-31137935000 USD20200511Open filing evidence
2018-07-01 – 2019-03-31399787000 USD20200511Open filing evidence
2018-10-01 – 2018-12-31135462000 USD20200206Open filing evidence
2018-07-01 – 2018-12-31261852000 USD20200206Open filing evidence
2018-07-01 – 2018-09-30126391000 USD2019-11-06 · 21:41:35.000ZOpen filing evidence
2017-07-01 – 2018-06-30482378000 USD20200826Open filing evidence
2018-01-01 – 2018-03-31123187000 USD20190507Open filing evidence
2017-07-01 – 2018-03-31348442000 USD20190507Open filing evidence
2017-10-01 – 2017-12-31117142000 USD20190207Open filing evidence
2017-07-01 – 2017-12-31225255000 USD20190207Open filing evidence
2017-07-01 – 2017-09-30108113000 USD20181107Open filing evidence
2016-07-01 – 2017-06-30419365000 USD20191106Open filing evidence

Consumables · Diagnostics And Genomics

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=tech:ConsumablesMember;us-gaap:StatementBusinessSegmentsAxis=tech:DiagnosticsAndGenomicsMember
PeriodValueUnitFiledEvidence
2020-07-01 – 2021-06-30194948000 USD20210825Open filing evidence
2019-07-01 – 2020-06-30171590000 USD20210825Open filing evidence
2018-07-01 – 2019-06-30158324000 USD20210825Open filing evidence
2017-07-01 – 2018-06-30150388000 USD20200826Open filing evidence
2016-07-01 – 2017-06-30134930000 USD20191106Open filing evidence

Consumables · Protein Sciences

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=tech:ConsumablesMember;us-gaap:StatementBusinessSegmentsAxis=tech:ProteinSciencesMember
PeriodValueUnitFiledEvidence
2020-07-01 – 2021-06-30557037000 USD20210825Open filing evidence
2019-07-01 – 2020-06-30431052000 USD20210825Open filing evidence
2018-07-01 – 2019-06-30430655000 USD20210825Open filing evidence
2017-07-01 – 2018-06-30384350000 USD20200826Open filing evidence
2016-07-01 – 2017-06-30341611000 USD20191106Open filing evidence

Reportable Segment · Biotechnology

Consolidation Items · Statement Business Segments

Source dimensions us-gaap:ConsolidationItemsAxis=tech:ReportableSegmentMember;us-gaap:StatementBusinessSegmentsAxis=tech:BiotechnologyMember
PeriodValueUnitFiledEvidence
2013-10-01 – 2013-12-3170557000 USD20140204Open filing evidence
2013-07-01 – 2013-12-31143747000 USD20140204Open filing evidence
2013-07-01 – 2013-09-3073190000 USD20131112Open filing evidence
2012-10-01 – 2012-12-3169628000 USD20140204Open filing evidence
2012-07-01 – 2012-12-31139131000 USD20140204Open filing evidence
2012-07-01 – 2012-09-3069503000 USD20131112Open filing evidence

Reportable Segment · Clinical Controls

Consolidation Items · Statement Business Segments

Source dimensions us-gaap:ConsolidationItemsAxis=tech:ReportableSegmentMember;us-gaap:StatementBusinessSegmentsAxis=tech:ClinicalControlsMember
PeriodValueUnitFiledEvidence
2013-10-01 – 2013-12-3113460000 USD20140204Open filing evidence
2013-07-01 – 2013-12-3125938000 USD20140204Open filing evidence
2013-07-01 – 2013-09-3012478000 USD20131112Open filing evidence
2012-10-01 – 2012-12-315455000 USD20140204Open filing evidence
2012-07-01 – 2012-12-3110977000 USD20140204Open filing evidence
2012-07-01 – 2012-09-305522000 USD20131112Open filing evidence

Material Reconciling Items · Biotechnology

Consolidation Items · Statement Business Segments

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:MaterialReconcilingItemsMember;us-gaap:StatementBusinessSegmentsAxis=tech:BiotechnologyMember
PeriodValueUnitFiledEvidence
2014-10-01 – 2014-12-3177951000 USD20150209Open filing evidence
2014-07-01 – 2014-12-31159419000 USD20150209Open filing evidence
2013-10-01 – 2013-12-3170557000 USD20150209Open filing evidence
2013-07-01 – 2013-12-31143747000 USD20150209Open filing evidence

Material Reconciling Items · Clinical Controls

Consolidation Items · Statement Business Segments

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:MaterialReconcilingItemsMember;us-gaap:StatementBusinessSegmentsAxis=tech:ClinicalControlsMember
PeriodValueUnitFiledEvidence
2014-10-01 – 2014-12-3113698000 USD20150209Open filing evidence
2014-07-01 – 2014-12-3127793000 USD20150209Open filing evidence
2013-10-01 – 2013-12-3113460000 USD20150209Open filing evidence
2013-07-01 – 2013-12-3125938000 USD20150209Open filing evidence

Material Reconciling Items · Protein Platforms

Consolidation Items · Statement Business Segments

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:MaterialReconcilingItemsMember;us-gaap:StatementBusinessSegmentsAxis=tech:ProteinPlatformsMember
PeriodValueUnitFiledEvidence
2014-10-01 – 2014-12-3120299000 USD20150209Open filing evidence
2014-07-01 – 2014-12-3133213000 USD20150209Open filing evidence
2013-10-01 – 2013-12-310 USD20150209Open filing evidence
2013-07-01 – 2013-12-310 USD20150209Open filing evidence

Operating Segments · Biotechnology

Consolidation Items · Statement Business Segments

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=tech:BiotechnologyMember
PeriodValueUnitFiledEvidence
2017-10-01 – 2017-12-31101411000 USD20180208Open filing evidence
2017-07-01 – 2017-12-31196487000 USD20180208Open filing evidence
2017-07-01 – 2017-09-3095076000 USD20171109Open filing evidence
2016-07-01 – 2017-06-30364504000 USD20170907Open filing evidence
2017-01-01 – 2017-03-3194516000 USD20170510Open filing evidence
2016-07-01 – 2017-03-31267256000 USD20170510Open filing evidence
2016-10-01 – 2016-12-3185953000 USD20180208Open filing evidence
2016-07-01 – 2016-12-31172740000 USD20180208Open filing evidence
2016-07-01 – 2016-09-3086787000 USD20171109Open filing evidence
2015-07-01 – 2016-06-30317340000 USD20170907Open filing evidence
2016-01-01 – 2016-03-3181386000 USD20170510Open filing evidence
2015-07-01 – 2016-03-31232984000 USD20170510Open filing evidence
2015-10-01 – 2015-12-3175854000 USD20170209Open filing evidence
2015-07-01 – 2015-12-31151597000 USD20170209Open filing evidence
2015-07-01 – 2015-09-3075743000 USD20161109Open filing evidence
2014-07-01 – 2015-06-30308437000 RestatedUSD20170907Open filing evidence
2015-01-01 – 2015-03-3178521000 RestatedUSD20160510Open filing evidence
2014-07-01 – 2015-03-31229347000 RestatedUSD20160510Open filing evidence
2014-10-01 – 2014-12-3174373000 USD20160209Open filing evidence
2014-07-01 – 2014-12-31150807000 USD20160209Open filing evidence
2014-07-01 – 2014-09-3076453000 RestatedUSD20151109Open filing evidence
2013-07-01 – 2014-06-30285142000 RestatedUSD20160829Open filing evidence
2014-01-01 – 2014-03-3180134000 USD20150511Open filing evidence
2013-07-01 – 2014-03-31223882000 RestatedUSD20150511Open filing evidence
2013-07-01 – 2013-09-3073190000 USD20141110Open filing evidence
2012-07-01 – 2013-06-30288156000 USD20150831Open filing evidence
2013-01-01 – 2013-03-3175285000 USD20140512Open filing evidence
2012-07-01 – 2013-03-31214416000 USD20140512Open filing evidence
2011-07-01 – 2012-06-30293274000 USD20140829Open filing evidence
2010-07-01 – 2011-06-30270287000 USD20130829Open filing evidence

Operating Segments · Clinical Controls

Consolidation Items · Statement Business Segments

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=tech:ClinicalControlsMember
PeriodValueUnitFiledEvidence
2015-07-01 – 2016-06-30104484000 USD20160829Open filing evidence
2016-01-01 – 2016-03-3129929000 USD20160510Open filing evidence
2015-07-01 – 2016-03-3176013000 USD20160510Open filing evidence
2015-10-01 – 2015-12-3125723000 USD20160209Open filing evidence
2015-07-01 – 2015-12-3146085000 USD20160209Open filing evidence
2015-07-01 – 2015-09-3020362000 USD20151109Open filing evidence
2014-07-01 – 2015-06-3077866000 RestatedUSD20160829Open filing evidence
2015-01-01 – 2015-03-3120001000 RestatedUSD20160510Open filing evidence
2014-07-01 – 2015-03-3156417000 RestatedUSD20160510Open filing evidence
2014-10-01 – 2014-12-3117297000 USD20160209Open filing evidence
2014-07-01 – 2014-12-3136406000 USD20160209Open filing evidence
2014-07-01 – 2014-09-3019119000 RestatedUSD20151109Open filing evidence
2013-07-01 – 2014-06-3072621000 RestatedUSD20160829Open filing evidence
2014-01-01 – 2014-03-3115421000 USD20150511Open filing evidence
2013-07-01 – 2014-03-3141358000 RestatedUSD20150511Open filing evidence
2013-07-01 – 2013-09-3012478000 USD20141110Open filing evidence
2012-07-01 – 2013-06-3022419000 USD20150831Open filing evidence
2013-01-01 – 2013-03-315707000 USD20140512Open filing evidence
2012-07-01 – 2013-03-3116684000 USD20140512Open filing evidence
2011-07-01 – 2012-06-3021286000 USD20140829Open filing evidence
2010-07-01 – 2011-06-3019675000 USD20130829Open filing evidence

Operating Segments · Diagnostics

Consolidation Items · Statement Business Segments

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=tech:DiagnosticsMember
PeriodValueUnitFiledEvidence
2017-10-01 – 2017-12-3123429000 USD20180208Open filing evidence
2017-07-01 – 2017-12-3148415000 USD20180208Open filing evidence
2017-07-01 – 2017-09-3024986000 USD20171109Open filing evidence
2016-07-01 – 2017-06-30107139000 USD20170907Open filing evidence
2017-01-01 – 2017-03-3125978000 USD20170510Open filing evidence
2016-07-01 – 2017-03-3174542000 USD20170510Open filing evidence
2016-10-01 – 2016-12-3124330000 USD20180208Open filing evidence
2016-07-01 – 2016-12-3148563000 USD20180208Open filing evidence
2016-07-01 – 2016-09-3024233000 USD20171109Open filing evidence
2015-07-01 – 2016-06-30104484000 USD20170907Open filing evidence
2016-01-01 – 2016-03-3129929000 USD20170510Open filing evidence
2015-07-01 – 2016-03-3176013000 USD20170510Open filing evidence
2015-10-01 – 2015-12-3125723000 USD20170209Open filing evidence
2015-07-01 – 2015-12-3146085000 USD20170209Open filing evidence
2015-07-01 – 2015-09-3020362000 USD20161109Open filing evidence
2014-07-01 – 2015-06-3077866000 USD20170907Open filing evidence

Operating Segments · Protein Platforms

Consolidation Items · Statement Business Segments

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=tech:ProteinPlatformsMember
PeriodValueUnitFiledEvidence
2017-10-01 – 2017-12-3129388000 USD20180208Open filing evidence
2017-07-01 – 2017-12-3154028000 USD20180208Open filing evidence
2017-07-01 – 2017-09-3024640000 USD20171109Open filing evidence
2016-07-01 – 2017-06-3091464000 USD20170907Open filing evidence
2017-01-01 – 2017-03-3123586000 USD20170510Open filing evidence
2016-07-01 – 2017-03-3164707000 USD20170510Open filing evidence
2016-10-01 – 2016-12-3121548000 USD20180208Open filing evidence
2016-07-01 – 2016-12-3141121000 USD20180208Open filing evidence
2016-07-01 – 2016-09-3019573000 USD20171109Open filing evidence
2015-07-01 – 2016-06-3077324000 USD20170907Open filing evidence
2016-01-01 – 2016-03-3119693000 USD20170510Open filing evidence
2015-07-01 – 2016-03-3155327000 USD20170510Open filing evidence
2015-10-01 – 2015-12-3119337000 USD20170209Open filing evidence
2015-07-01 – 2015-12-3135634000 USD20170209Open filing evidence
2015-07-01 – 2015-09-3016296000 USD20161109Open filing evidence
2014-07-01 – 2015-06-3066249000 RestatedUSD20170907Open filing evidence
2015-01-01 – 2015-03-3115669000 USD20160510Open filing evidence
2014-07-01 – 2015-03-3149061000 USD20160510Open filing evidence
2014-10-01 – 2014-12-3120478000 USD20160209Open filing evidence
2014-07-01 – 2014-12-3133382000 USD20160209Open filing evidence
2014-07-01 – 2014-09-3012914000 USD20151109Open filing evidence
2013-07-01 – 2014-06-300 USD20160829Open filing evidence
2013-07-01 – 2013-09-300 USD20141110Open filing evidence
2012-07-01 – 2013-06-300 USD20150831Open filing evidence

CN

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=country:CN
PeriodValueUnitFiledEvidence
2011-07-01 – 2012-06-3011378000 USD20120829Open filing evidence
2010-07-01 – 2011-06-308299000 USD20120829Open filing evidence
2009-07-01 – 2010-06-306792000 USD20120829Open filing evidence

US

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=country:US
PeriodValueUnitFiledEvidence
2011-07-01 – 2012-06-30172310000 USD20120829Open filing evidence
2010-07-01 – 2011-06-30159857000 USD20120829Open filing evidence
2009-07-01 – 2010-06-30148137000 USD20120829Open filing evidence

Biotechnology

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=tech:BiotechnologyMember
PeriodValueUnitFiledEvidence
2013-01-01 – 2013-03-3175285000 USD20130510Open filing evidence
2012-07-01 – 2013-03-31214416000 USD20130510Open filing evidence
2012-10-01 – 2012-12-3169628000 USD20130211Open filing evidence
2012-07-01 – 2012-12-31139131000 USD20130211Open filing evidence
2012-07-01 – 2012-09-3069503000 USD20121109Open filing evidence
2011-07-01 – 2012-06-30293274000 USD20120829Open filing evidence
2012-01-01 – 2012-03-3178180000 USD20130510Open filing evidence
2011-07-01 – 2012-03-31220291000 USD20130510Open filing evidence
2011-10-01 – 2011-12-3169808000 USD20130211Open filing evidence
2011-07-01 – 2011-12-31142111000 USD20130211Open filing evidence
2011-07-01 – 2011-09-3072303000 USD20121109Open filing evidence
2010-07-01 – 2011-06-30270287000 USD20120829Open filing evidence
2011-01-01 – 2011-03-3171120000 USD20120510Open filing evidence
2010-07-01 – 2011-03-31197241000 USD20120510Open filing evidence
2010-10-01 – 2010-12-3163080000 USD20120207Open filing evidence
2010-07-01 – 2010-12-31126121000 USD20120207Open filing evidence
2010-07-01 – 2010-09-3063041000 USD20111109Open filing evidence
2009-07-01 – 2010-06-30250653000 USD20120829Open filing evidence
2008-07-01 – 2009-06-30246454000 USD20110829Open filing evidence

Europe

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=tech:EuropeMember
PeriodValueUnitFiledEvidence
2011-07-01 – 2012-06-3090142000 USD20120829Open filing evidence
2010-07-01 – 2011-06-3083676000 USD20120829Open filing evidence
2009-07-01 – 2010-06-3078496000 USD20120829Open filing evidence

Hematology

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=tech:HematologyMember
PeriodValueUnitFiledEvidence
2013-01-01 – 2013-03-315707000 USD20130510Open filing evidence
2012-07-01 – 2013-03-3116684000 USD20130510Open filing evidence
2012-10-01 – 2012-12-315455000 USD20130211Open filing evidence
2012-07-01 – 2012-12-3110977000 USD20130211Open filing evidence
2012-07-01 – 2012-09-305522000 USD20121109Open filing evidence
2011-07-01 – 2012-06-3021286000 USD20120829Open filing evidence
2012-01-01 – 2012-03-315441000 USD20130510Open filing evidence
2011-07-01 – 2012-03-3115588000 USD20130510Open filing evidence
2011-10-01 – 2011-12-314854000 USD20130211Open filing evidence
2011-07-01 – 2011-12-3110147000 USD20130211Open filing evidence
2011-07-01 – 2011-09-305293000 USD20121109Open filing evidence
2010-07-01 – 2011-06-3019675000 USD20120829Open filing evidence
2011-01-01 – 2011-03-315151000 USD20120510Open filing evidence
2010-07-01 – 2011-03-3114683000 USD20120510Open filing evidence
2010-10-01 – 2010-12-314628000 USD20120207Open filing evidence
2010-07-01 – 2010-12-319532000 USD20120207Open filing evidence
2010-07-01 – 2010-09-304904000 USD20111109Open filing evidence
2009-07-01 – 2010-06-3018394000 USD20120829Open filing evidence
2008-07-01 – 2009-06-3017502000 USD20110829Open filing evidence

Other Asia

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=tech:OtherAsiaMember
PeriodValueUnitFiledEvidence
2011-07-01 – 2012-06-3025988000 USD20120829Open filing evidence
2010-07-01 – 2011-06-3024715000 USD20120829Open filing evidence
2009-07-01 – 2010-06-3022372000 USD20120829Open filing evidence

Other Revenues From Business Held For Sale

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=tech:OtherRevenuesFromBusinessHeldForSaleMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2025-03-314152000 USD20250508Open filing evidence
2024-10-01 – 2024-12-311849000 USD20250206Open filing evidence
2024-07-01 – 2024-12-314152000 USD20250206Open filing evidence
2024-07-01 – 2024-09-302303000 USD20241105Open filing evidence
2023-07-01 – 2024-06-304153000 USD20240822Open filing evidence
2024-01-01 – 2024-03-312093000 USD20250508Open filing evidence
2023-07-01 – 2024-03-312093000 USD20250508Open filing evidence

Rest Of World

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=tech:RestOfWorldMember
PeriodValueUnitFiledEvidence
2011-07-01 – 2012-06-3014742000 USD20120829Open filing evidence
2010-07-01 – 2011-06-3013415000 USD20120829Open filing evidence
2009-07-01 – 2010-06-3013250000 USD20120829Open filing evidence